SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors

Purpose: We have previously shown that supraoptimal signaling of high avidity T cells leads to high expression of PD-1 and inhibition of proliferation. This study was designed to see if this effect could be mitigated by combining a vaccine that stimulates high avidity T cells with PD-1 blockade....

Full description

Bibliographic Details
Main Authors: Xue, Wei, Brentville, Victoria A., Symonds, Peter, Cook, Katherine, Yagita, Hideo, Metheringham, Rachael L., Durrant, Lindy
Format: Article
Published: Impact Journals 2016
Subjects:
Online Access:https://eprints.nottingham.ac.uk/49786/
_version_ 1848798077569204224
author Xue, Wei
Brentville, Victoria A.
Symonds, Peter
Cook, Katherine
Yagita, Hideo
Metheringham, Rachael L.
Durrant, Lindy
author_facet Xue, Wei
Brentville, Victoria A.
Symonds, Peter
Cook, Katherine
Yagita, Hideo
Metheringham, Rachael L.
Durrant, Lindy
author_sort Xue, Wei
building Nottingham Research Data Repository
collection Online Access
description Purpose: We have previously shown that supraoptimal signaling of high avidity T cells leads to high expression of PD-1 and inhibition of proliferation. This study was designed to see if this effect could be mitigated by combining a vaccine that stimulates high avidity T cells with PD-1 blockade. Experimental Design: We investigated the anti-tumor effect of a huIgG1 antibody DNA vaccine (SCIB1) and PD-1 blockade. Results: Vaccination of HLA-DR4 transgenic mice with SCIB1 induced high frequency and avidity T cell responses that resulted in survival (40%) of mice with established B16F1-DR4 tumors. SCIB1 vaccination was associated with increased infiltration of CD4 and CD8 T cells within the tumor but was also associated with upregulation of PD-L1 within the tumor environment. PD-1 blockade also resulted in increased CD8 T cell infiltration and an anti-tumor response with 50% of mice showing long term survival. In line with our hypothesis that PD-1/PD-L1 signaling results in inhibition of proliferation of high avidity T cells at the tumor site, the combination of PD-1 blockade with vaccination, enhanced the number and proliferation of the CD8 tumor infiltrate. This resulted in a potent anti-tumor response with 80% survival of the mice. Conclusions: There is a benefit in combining PD-1 blockade with vaccines that induce high avidity T cell responses and in particular with SCIB1.
first_indexed 2025-11-14T20:14:02Z
format Article
id nottingham-49786
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:14:02Z
publishDate 2016
publisher Impact Journals
recordtype eprints
repository_type Digital Repository
spelling nottingham-497862020-05-04T18:22:30Z https://eprints.nottingham.ac.uk/49786/ SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors Xue, Wei Brentville, Victoria A. Symonds, Peter Cook, Katherine Yagita, Hideo Metheringham, Rachael L. Durrant, Lindy Purpose: We have previously shown that supraoptimal signaling of high avidity T cells leads to high expression of PD-1 and inhibition of proliferation. This study was designed to see if this effect could be mitigated by combining a vaccine that stimulates high avidity T cells with PD-1 blockade. Experimental Design: We investigated the anti-tumor effect of a huIgG1 antibody DNA vaccine (SCIB1) and PD-1 blockade. Results: Vaccination of HLA-DR4 transgenic mice with SCIB1 induced high frequency and avidity T cell responses that resulted in survival (40%) of mice with established B16F1-DR4 tumors. SCIB1 vaccination was associated with increased infiltration of CD4 and CD8 T cells within the tumor but was also associated with upregulation of PD-L1 within the tumor environment. PD-1 blockade also resulted in increased CD8 T cell infiltration and an anti-tumor response with 50% of mice showing long term survival. In line with our hypothesis that PD-1/PD-L1 signaling results in inhibition of proliferation of high avidity T cells at the tumor site, the combination of PD-1 blockade with vaccination, enhanced the number and proliferation of the CD8 tumor infiltrate. This resulted in a potent anti-tumor response with 80% survival of the mice. Conclusions: There is a benefit in combining PD-1 blockade with vaccines that induce high avidity T cell responses and in particular with SCIB1. Impact Journals 2016-11-04 Article PeerReviewed Xue, Wei, Brentville, Victoria A., Symonds, Peter, Cook, Katherine, Yagita, Hideo, Metheringham, Rachael L. and Durrant, Lindy (2016) SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget, 7 (50). pp. 83088-83100. ISSN 1949-2553 DNA vaccine; Fc targeting; PD-1 blockade; melanoma; tumor rejection http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13070&path[]=41414 doi:10.18632/oncotarget.13070 doi:10.18632/oncotarget.13070
spellingShingle DNA vaccine; Fc targeting; PD-1 blockade; melanoma; tumor rejection
Xue, Wei
Brentville, Victoria A.
Symonds, Peter
Cook, Katherine
Yagita, Hideo
Metheringham, Rachael L.
Durrant, Lindy
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
title SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
title_full SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
title_fullStr SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
title_full_unstemmed SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
title_short SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
title_sort scib1, a huigg1 antibody dna vaccination, combined with pd-1 blockade induced efficient therapy of poorly immunogenic tumors
topic DNA vaccine; Fc targeting; PD-1 blockade; melanoma; tumor rejection
url https://eprints.nottingham.ac.uk/49786/
https://eprints.nottingham.ac.uk/49786/
https://eprints.nottingham.ac.uk/49786/